Iguana Healthcare Management’s Esperion Therapeutics ESPR Stock Holding History

Iguana Healthcare Management’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	$7.23M	Sell	100,000 -65,000	-39%	-$4.77M	4.76%	2
2017 Q4	$10.9M	Buy	165,000 +15,000	+10%	+$808K	7.08%	1
2017 Q3	$7.52M	Buy	150,000 +50,000	+50%	+$2.41M	4.1%	2
2017 Q2	$4.63M	Buy	100,000 +25,000	+33%	+$919K	2.62%	14
2017 Q1	$2.65M	Buy	+75,000	New	+$1.72M	1.31%	26
2016 Q4	–	Sell	-80,000	Closed	-$1.11M	–	67
2016 Q3	$1.11M	Buy	+80,000	New	+$907K	0.2%	75
2015 Q4	–	Sell	-50,000	Closed	-$1.18M	–	70
2015 Q3	$1.18M	Sell	50,000 -100,000	-67%	-$6.28M	0.46%	54
2015 Q2	$12.3M	Sell	150,000 -50,000	-25%	-$4.89M	3.87%	6
2015 Q1	$18.5M	Hold	200,000	–	–	7.79%	2
2014 Q4	$8.09M	Buy	200,000 +75,000	+60%	+$2.3M	3.91%	7
2014 Q3	$3.06M	Hold	125,000	–	–	1.63%	20
2014 Q2	$1.98M	Sell	125,000 -10,000	-7%	-$144K	0.92%	40
2014 Q1	$2.04M	Sell	135,000 -15,000	-10%	-$233K	0.94%	38
2013 Q4	$2.06M	Buy	+150,000	New	+$2.18M	1.17%	29

Other funds holding ESPR

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Iguana Healthcare Management's ESPR Position: Q1 2018 in Review

Iguana Healthcare Management reduced its Esperion Therapeutics (ESPR) stake by 39% in Q1 2018, selling an estimated $4.77M and leaving 100,000 shares worth $7.23M. The position accounts for 4.76% of the portfolio, ranked #2.

Iguana Healthcare Management first reported a position in ESPR in Q4 2013 and has held it in 14 quarters since. The position peaked at $18.5M in Q1 2015. 187 funds tracked by Wall St. Rank hold ESPR as of Q1 2018.

Iguana Healthcare Management held 100,000 shares of Esperion Therapeutics worth $7.23M as of Q1 2018.
Iguana Healthcare Management sold 65,000 Esperion Therapeutics shares in Q1 2018, an estimated $4.77M.
Esperion Therapeutics made up 4.76% of Iguana Healthcare Management's portfolio in Q1 2018, its #2 holding.
Iguana Healthcare Management first reported a position in Esperion Therapeutics in Q4 2013 and has held it in 14 quarters since.
Iguana Healthcare Management's Esperion Therapeutics position peaked at $18.5M in Q1 2015.
187 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2018.

Based on Iguana Healthcare Management's 13F filing for Q1 2018, filed 15 May 2018.